Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
9.79
+0.32 (3.38%)
At close: Jun 26, 2026, 4:00 PM EDT
10.00
+0.21 (2.15%)
After-hours: Jun 26, 2026, 7:52 PM EDT
Candel Therapeutics Employees
Candel Therapeutics had 55 employees as of December 31, 2025. The number of employees increased by 17 or 44.74% compared to the previous year.
Employees
55
Change (1Y)
17
Growth (1Y)
44.74%
Revenue / Employee
n/a
Profits / Employee
-$989,491
Market Cap
717.32M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Rigel Pharmaceuticals | 174 |
| Allogene Therapeutics | 152 |
| Aclaris Therapeutics | 73 |
| CytomX Therapeutics | 69 |
| SpyGlass Pharma | 68 |
| Oculis Holding AG | 60 |
| Climb Bio | 29 |
| Immix Biopharma | 21 |
CADL News
- 3 days ago - Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer - GlobeNewsWire
- 5 days ago - Candel Therapeutics Transcript: AGM 2026 - Transcripts
- 24 days ago - Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 26 days ago - Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene - TheFly
- 26 days ago - Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer - GlobeNewsWire
- 26 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Candel Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts
- 5 weeks ago - Candel Therapeutics price target raised to $9 from $7 at BofA - TheFly